Nature Reviews Drug Discovery contents April 2013 Volume 12 Number 4 pp 245-324

Advertisement
Reichert Surface Plasmon Resonance (SPR) systems drive research - from discovery to development to production Monitor binding events in real-time and obtain detailed interaction information - kinetics (on/off rates), affinity and thermodynamics. Guide your drug discovery process with Reichert's ultra-sensitive and affordable SPR systems. ReichertSPR.com
TABLE OF CONTENTS
April 2013 Volume 12 Number 4
Impact Factor 29.008 *	In this issue Comment News and Analysis Research Highlights Reviews Correspondence Also this month Featured article: A guide to drug discovery  Featured article: Adenosine receptors as drug targets — what are the challenges? Jiang-Fan Chen, Holger K. Eltzschig & Bertil B. Fredholm
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
CNIO, Nature, Nature Cell Biology and Nature Reviews Cancer present: CNIO Cancer Symposium: Frontiers in Tumor Heterogeneity and Plasticity October 27-30, 2013 Madrid, Spain Click here for more information or to register for this conference today!
In this issue p245 | doi:10.1038/nrd3997 Full Text
Comment: Susan R. Forda, Richard Bergström, Magda Chlebus, Richard Barker & Peter Høngaard Andersen p247 | doi:10.1038/nrd3981 Improved R&D models, supported by appropriate regulatory pathways, are needed to provide new drugs with greater efficiency, in a framework that is financially viable for all stakeholders. Here, we present the perspective of the European Federation of Pharmaceutical Industries and Associations on the key areas on which to focus to achieve this. Full Text | PDF Priorities for improving drug research, development and regulation
NEWS AND ANALYSIS		Top
Antibody drugs set to revive flagging migraine target Elie Dolgin p249 | doi:10.1038/nrd3991 CGRP makes a comeback as antibodies advance into Phase II trials. PDF
Anticancer IGF1R classes take more knocks Malini Guha p250 | doi:10.1038/nrd3992 Disappointing developments with Amgen's ganitumab and Bristol-Myers Squibb's BMS-754807 highlight the need for rational combinations and predictive biomarkers to rescue IGF1R pathway antagonists. PDF
Molecular imaging as a de-risking tool: coming into focus? Asher Mullard p251 | doi:10.1038/nrd3993 Molecular imaging is already engrained in early-stage trials for central nervous system disorders, but used infrequently in other therapeutic areas. What will it take to make it standard practice across the pipeline? PDF
NEWS IN BRIEF Rare disease bonanza | Eye on ibrutinib | Resolving sirtuin uncertainty? p253 | doi:10.1038/nrd3994 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q2 2013 Karen Nguyen p254 | doi:10.1038/nrd3990 PDF
BIOBUSINESS BRIEFS Deal watch: Chiasma and Roche partner in oral peptide drug delivery Charlotte Harrison p255 | doi:10.1038/nrd3989 PDF
PATENT WATCH Australia allows isolated gene patents | United States rings in 'first to file' changes | Animal models Charlotte Harrison p256 | doi:10.1038/nrd3995 PDF
AN AUDIENCE WITH Paul Stoffels p258 | doi:10.1038/nrd3996 Paul Stoffels, Johnson & Johnson's Chief Scientific Officer, discusses the company's approach to partnering. PDF
FROM THE ANALYST'S COUCH Antibody-drug conjugates Rachel S. Zolot, Satarupa Basu & Ryan P. Million p259 | doi:10.1038/nrd3980 Antibody-drug conjugates (ADCs), which allow cytotoxic drugs to be selectively targeted to cancer cells, are attracting considerable interest. This article analyses the pipeline of ADCs, as well as trends in collaborations and deals related to ADC platforms. PDF
RESEARCH HIGHLIGHTS Top Metabolic disorders: Breaking the links between inflammation and diabetes p261 | doi:10.1038/nrd3988 PDF Blood disorders: Epigenetically enhancing haemoglobin production p262 | doi:10.1038/nrd3998 PDF Radiation injury: EGF aids recovery after blast of radiation p262 | doi:10.1038/nrd3999 PDF Cancer: Activating Notch ameliorates AML p263 | doi:10.1038/nrd3982 PDF Nanotechnology: Biological proteins knock nanoparticles off target p264 | doi:10.1038/nrd3983 PDF IN BRIEF Inflammatory disorders: Of mice and humans | Lead identification: New inhibitors of sonic hedgehog signalling | Pharmacokinetics: Single-cell imaging adds insight into drug action | Cardiovascular disease: Secrets of an ageing heart PDF Drug Discovery JOBS of the week Postdoctoral Fellow in structure-based drug design by NMR EMBL (European Molecular Biology Laboratory) Postdoctoral Positions in Drug Discovery Research (1-2) Shanghai Jiaotong University Research Assistant IRB Barcelona Research Fellow in Physical Oceanography (Dynamics of the Ocean Surface Boundary Level) National Oceanography Centre Southampton More Science jobs from Drug Discovery EVENT Resources for Computational Drug Discovery 12.09.13 Cambridge, UK More science events from
REVIEWS		Top
Adenosine receptors as drug targets — what are the challenges? Jiang-Fan Chen, Holger K. Eltzschig & Bertil B. Fredholm p265 | doi:10.1038/nrd3955 Adenosine signalling has a functional role in many diseases and has long been a target for drug development. However, only one adenosine receptor-specific agent has so far gained approval. Here, Fredholm and colleagues provide an overview of the physiological and pathological functions of adenosine and consider the challenges in the development of compounds targeting adenosine receptors. Abstract | Full Text | PDF | Supplementary information
Advertisement
Bio-Rad's real-time PCR detection systems give you the best results possible - quickly and easily. Enjoy a new degree of quality, usability and peace of mind. Click here to learn more.
Article series: A guide to drug discovery Animal models for metabolic, neuromuscular and ophthalmological rare diseases >Guillaume Vaquer, Frida Rivière, Maria Mavris, Fabrizia Bignami, Jordi Llinares-Garcia, Kerstin Westermark & Bruno Sepodes p287 | doi:10.1038/nrd3831 Animal models are vital tools in the development of therapies for orphan diseases, given the small populations of patients available to evaluate the therapies. Here, Sepodes and colleagues from the European Medicines Agency's Committee for Orphan Medicinal Products harness their experience to provide an overview of the animal models used to support regulatory applications for metabolic, neuromuscular and ophthalmological rare diseases. Abstract | Full Text | PDF
Challenges and approaches for the development of safer immunomodulatory biologics Jean G. Sathish, Swaminathan Sethu, Marie-Christine Bielsky, Lolke de Haan, Neil S. French, Karthik Govindappa, James Green, Christopher E. M. Griffiths, Stephen Holgate, David Jones, Ian Kimber, Jonathan Moggs, Dean J. Naisbitt, Munir Pirmohamed, Gabriele Reichmann, Jennifer Sims, Meena Subramanyam, Marque D. Todd, Jan Willem Van Der Laan, Richard J. Weaver & B. Kevin Park p306 | doi:10.1038/nrd3974 Owing to their specificity, immunomodulatory biologics generally have better safety profiles than small-molecule drugs. However, adverse effects such as an increased risk of infections or cytokine release syndrome are of concern. Here, Park and colleagues discuss the current strategies used to predict and mitigate these adverse effects and consider how they can be used to inform the development of safer immunomodulatory biologics. Abstract | Full Text | PDF | Supplementary information
CORRESPONDENCE		Top
Correspondence: Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease Paul S. Aisen, Bruno Vellas & Harald Hampel p324 | doi:10.1038/nrd3842-c1 Full Text | PDF
Advertisement
Nature Publishing Group and Relay Technology Management present: The Epigenetics Target Explorer Click here to access this free online tool and the accompanying article in Nature Reviews Drug Discovery.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2011 Journal Citation Report (Thomson Reuters, 2012)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.